Fourth study published over two-year span that analyzes key leukemia protein
Northwestern Medicine scientists have discovered two successful therapies that slowed the progression of pediatric leukemia in mice, according to three studies published over the last two years in the journal Cell, and the final paper published Dec. 20 in Genes & Development.
When a key protein responsible for leukemia, MLL, is stabilized, it slows the progression of the leukemia, the most recent study found. The next step will be to combine the treatments from the past two years of research into a pediatric leukemia “super drug” to test on humans in a clinical trial.
The survival rate is only 30 percent for children diagnosed with MLL-translocation leukemia, a cancer that affects the blood and bone marrow. Patients with leukemia have a very low percentage of red blood cells, making them anemic, and have approximately 80 times more white blood cells than people without cancer.
30%Current survival rate for pediatric leukemia patients.
“These white blood cells infiltrate many of the tissues and organs of the affected individuals and is a major cause of death in leukemia patients,” said senior author Ali Shilatifard, the Robert Francis Furchgott Professor of Biochemistry and Molecular Genetics and Pediatrics, the chairman of biochemistry and molecular genetics and the director of Northwestern’s Simpson Querrey Center for Epigenetics. “This is a monster cancer that we’ve been dealing with for many years in children.”
There are several types of leukemia. This research focused on the two most common found in infants through teenagers: acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).
For the past 25 years, Shilatifard’s laboratory has been studying the molecular function of MLL within its complex known as COMPASS (Complex Proteins Associated with Set1). Most recently, it was demonstrated that COMPASS components are one of the most frequently identified mutations in cancer.The next step of this work will be to bring the drug to a clinical trial setting, which Shilatifard said he hopes will happen in the next three to five years.
“I’ve been working on this translocation for more than two decades, and we’re finally at the point where in five to 10 years, we can get a drug in kids that can be effective,” Shilatifard said. “If we can bring that survival rate up to 85 percent, that’s a major accomplishment.”
Earlier work from Shilatifard’s laboratory published in Cell in 2018 identified compounds that could slow cancer growth by interrupting a gene transcription process known as “Super Elongation Complex” (SEC). It was the first compound in its class to do this.
This MLL stabilization process discovered in the most recent paper could potentially work in cancers with solid tumors, such as breast or prostate cancer, said first author Zibo Zhao, a postdoctoral research fellow in Shilatifard’s lab.
“This opens up a new therapeutic approach not only for leukemia, which is so important for the many children who are diagnosed with this terrible cancer, but also for other types of cancers that plague the population,” Zhao said.
“The publication of these four papers and the possibility of a future human clinical trial could not have happened if it weren’t for the cross-disciplinary collaboration at Northwestern,” Shilatifard said.
The Latest on: Pediatric leukemia
via Google News
The Latest on: Pediatric leukemia
- 'It isn't a disability, it is a new ability': Norfolk children share experiences on World Sight Dayon October 14, 2021 at 4:44 am
The charity Vision Norfolk supports more than 4000 visually-impaired people in the county every year - including more than 500 children. | ITV News Anglia ...
- Woori employees donate blood for children with canceron October 14, 2021 at 12:35 am
Woori Financial Group said Thursday that it donated 500 blood donation cards to the Korea Childhood Leukemia Foundation. Woori group's vice president Choi Dong-soo delivered the donation cards to the ...
- Children’s Hospital researchers create new app for families facing canceron October 13, 2021 at 3:24 pm
When you look at Cole Murphy playing baseball, he seems like a typical 6 year old boy, but he’s been facing been battling cancer for years. “Cole was diagnosed with leukemia when he was 3,” explains ...
- Nilotinib Treatment May Cause Growth Deceleration in Children With Chronic Myelogenous Leukemiaon October 13, 2021 at 8:30 am
Researchers sought to determine whether pediatric patients with CML may have attenuated growth when receiving treatment with nilotinib.
- FSU lineman and leukemia survivor Brady Scott helping family going through similar plighton October 12, 2021 at 6:00 am
Florida State offensive lineman Brady Scott has linked up with teammate Dillan Gibbons to support a teenager fighting leukemia like he did as a child.
- True definition of a Riser: Local pediatric cancer patient serenaded by country staron October 11, 2021 at 8:38 pm
One New Riegel girl who is battling leukemia got to share a stage with a country singer. Dierks Bentley sang to 7-year-old Myla Brickner in front of a crowd of thousands during his concert in ...
- Pediatric cancer in NJ getting more attention and funding with new lawson October 10, 2021 at 4:18 pm
According to the Centers for Disease Control and Prevention, New Jersey has the third highest rate of pediatric cancer in the nation.
- Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemiaon October 9, 2021 at 11:43 am
Pediatric de novo acute myeloid leukemia (AML) is an aggressive malignancy with current therapy resulting in cure rates of only 60%. To better understand the cause of the marked heterogeneity in ...
- Genetic rescue, a 'natural gene therapy,' suggests possible new approach to pediatric MDSon October 7, 2021 at 10:03 am
Researchers have discovered a battle waged within the blood systems of children who inherit mutations in the genes SAMD9 and SAMD9L. The outcomes have life-or-death consequences for patients.
- Risk of Leukemia in Children with Down Syndromeon October 4, 2021 at 3:00 am
Children with Down syndrome have a higher risk of developing leukemia. Learn more about the symptoms, treatments, and risk of recurrence.
via Bing News